We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA REQUIRES NEW WARNINGS IN ZELNORM LABELING
FDA REQUIRES NEW WARNINGS IN ZELNORM LABELING
April 28, 2004
The FDA yesterday said it was requiring the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate), the only agency-approved drug for the short-term treatment of women with irritable bowel syndrome.